UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 51

Sortiert nach

Correction: A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer

BMC medical research methodology, 2023-09, Vol.23 (1), p.1-202, Article 202

2023

Volltextzugriff (PDF)

Abstract PD4-12: Clustering of activated proteins of the PI3K and MAPK pathways distinguishes ER+/HER2- primary breast cancer patients with preferential tamoxifen benefit

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD4-12-PD4-12

2018

Volltextzugriff (PDF)

Abstract P1-13-10: Adjuvant treatment of HER2+ breast cancer: Should trastuzumab be given sequentially or concurrently with chemotherapy?

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-13-10

2018

Volltextzugriff (PDF)

Abstract P4-08-06: Phosphorylation of insulin-like growth factor-1 receptor (IGF-1R) is associated with tamoxifen resistance by activating the PI3K/MAPK pathway

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P4-P4-08-06

2018

Volltextzugriff (PDF)

Abstract P2-09-16: How population-based data complement trial data in the adjuvant endocrine treatment of ER+/HER2+ breast cancers

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P2-P2-09-16

2017

Volltextzugriff (PDF)

Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-30

2017

Volltextzugriff (PDF)

Abstract OT1-01-08: Intensified alkylating chemotherapy in patients with oligo-metastatic breast cancer harboring homologous recombination deficiency: The OLIGO study

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT1-01-08-OT1-01-08

2017

Volltextzugriff (PDF)

Outside director compensation policy and the investment opportunity set

Journal of corporate finance (Amsterdam, Netherlands), 2005-09, Vol.11 (4), p.680-715

2005

Volltextzugriff (PDF)

Abstract P1-06-07: Characterization of chromosomal instability in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P1-P1-06-07

2019

Volltextzugriff (PDF)

Abstract S6-06: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat?

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.S6-S6-06

2016

Volltextzugriff (PDF)

Abstract PD5-02: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat?

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.PD5-02-PD5-02

2016

Volltextzugriff (PDF)

Abstract OT1-03-10: A phase I followed by a r andomiz e d phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy v ersus capec i tabine in BRCA-1 or -2 mutated Her2 negative ad v anced breast c a ncer as first l ine treatment (REVIVAL study)

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.OT1-03-10-OT1-03-10

2016

Volltextzugriff (PDF)

Abstract P4-14-11: No impact of osteoporosis or bisphosphonate use for osteoporosis on breast cancer outcome: A sub-study of the DATA trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-14-11

2019

Volltextzugriff (PDF)

Abstract OT2-07-08: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT2-07-08-OT2-07-08

2018

Volltextzugriff (PDF)

Abstract P1-14-16: Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P1-P1-14-16

2016

Volltextzugriff (PDF)

Abstract P3-07-28: BRCA1-like profile as predictive biomarker in non myeloablative chemotherapy (GAIN study)

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-07-28

2016

Volltextzugriff (PDF)

Abstract S3-05: Higher 10-year overall survival after breast conserving therapy compared to mastectomy in early stage breast cancer: A population-based study with 37,207 patients

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.S3-S3-05

2016

Volltextzugriff (PDF)

Abstract P6-08-06: Neoadjuvant tamoxifen therapy synchronizes ERα binding and gene expression profiles

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P6-P6-08-06

2016

Volltextzugriff (PDF)

Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT2-01-11-OT2-01-11

2017

Volltextzugriff (PDF)

Abstract S1-03: First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.S1-S1-03

2017

Volltextzugriff (PDF)

Abstract S6-02: The efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer. First results of the TEAM IIB trial (BOOG 2006-04)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.S6-S6-02

2017

Volltextzugriff (PDF)

Abstract P5-14-03: Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P5-P5-14-03

2017

Volltextzugriff (PDF)

Abstract P5-08-07: The long-term prognosis of breast cancers patients diagnosed ≤40 years in the absence of adjuvant systemic therapy

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P5-P5-08-07

2017

Volltextzugriff (PDF)

Abstract PD01-02: Increased expression of phosporylated mTOR in metastatic breast tumors compared to primary tumors in patients who received adjuvant endocrine therapy

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.PD01-02-PD01-02

2012

Volltextzugriff (PDF)

Abstract OT1-1-01: Optimizing neoadjuvant systemic treatment in HER2 positive breast cancer - The TRAIN-2 study

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.OT1-1-01-OT1-1-01

2013

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Nur zeigenMit Volltextzugriff

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Publikationsform

Artikel
(51)

Sprache

Erscheinungsjahr

n.n

Thema

Business & Economics
(15)
Social Sciences
(15)
Economics
(13)
Business, Finance
(12)
Studies
(9)
Northern America
(7)
U.S
(7)
Mathematical Models
(5)
Stock Prices
(5)
Theorie
(5)
Usa
(5)
Economic Theory
(3)
Finance
(3)
Financial Economics
(3)
Firm
(3)
Mergers, Acquisitions, Restructuring, Voting, Proxy Contests, Corporate Governance
(3)
Stock Offerings
(3)
U.S.A
(3)
Arbitrage
(2)
Asset Pricing, Trading Volume, Bond Interest Rates
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Correction: A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer

Abstract PD4-12: Clustering of activated proteins of the PI3K and MAPK pathways distinguishes ER+/HER2- primary breast cancer patients with preferential tamoxifen benefit

Abstract P1-13-10: Adjuvant treatment of HER2+ breast cancer: Should trastuzumab be given sequentially or concurrently with chemotherapy?

Abstract P4-08-06: Phosphorylation of insulin-like growth factor-1 receptor (IGF-1R) is associated with tamoxifen resistance by activating the PI3K/MAPK pathway

Abstract P2-09-16: How population-based data complement trial data in the adjuvant endocrine treatment of ER+/HER2+ breast cancers

Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle

Abstract OT1-01-08: Intensified alkylating chemotherapy in patients with oligo-metastatic breast cancer harboring homologous recombination deficiency: The OLIGO study

Outside director compensation policy and the investment opportunity set

Abstract P1-06-07: Characterization of chromosomal instability in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

Abstract S6-06: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat?

Abstract PD5-02: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat?

Abstract OT1-03-10: A phase I followed by a r andomiz e d phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy v ersus capec i tabine in BRCA-1 or -2 mutated Her2 negative ad v anced breast c a ncer as first l ine treatment (REVIVAL study)

Abstract P4-14-11: No impact of osteoporosis or bisphosphonate use for osteoporosis on breast cancer outcome: A sub-study of the DATA trial

Abstract OT2-07-08: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial

Abstract P1-14-16: Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study

Abstract P3-07-28: BRCA1-like profile as predictive biomarker in non myeloablative chemotherapy (GAIN study)

Abstract S3-05: Higher 10-year overall survival after breast conserving therapy compared to mastectomy in early stage breast cancer: A population-based study with 37,207 patients

Abstract P6-08-06: Neoadjuvant tamoxifen therapy synchronizes ERα binding and gene expression profiles

Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Abstract S1-03: First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer

Abstract S6-02: The efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer. First results of the TEAM IIB trial (BOOG 2006-04)

Abstract P5-14-03: Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04)

Abstract P5-08-07: The long-term prognosis of breast cancers patients diagnosed ≤40 years in the absence of adjuvant systemic therapy

Abstract PD01-02: Increased expression of phosporylated mTOR in metastatic breast tumors compared to primary tumors in patients who received adjuvant endocrine therapy

Abstract OT1-1-01: Optimizing neoadjuvant systemic treatment in HER2 positive breast cancer - The TRAIN-2 study

Aktive Filter

Suchergebnisse filtern